ST Wanbang (002082.SZ) subsidiary WP107 drug multi-dose climbing clinical study obtained FDA approval

Zhitong Finance App News, ST Wanbang (002082.SZ) announced that Wanbang Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, independently developed a new drug WP107 (Huperzine A oral solution) for the treatment of systemic myasthenia gravis, which was recently approved by the US Food and Drug Administration (“FDA”) for multi-dose hill climbing clinical trial studies on health trial participants.

According to reports, this multi-dose climbing clinical study approved by the FDA is a placebo-controlled single-center, randomized, double-blind, multiple-dose, dose-increasing pharmacokinetic study. The purpose is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the preparation for multiple doses of the oral solution of Huperzine A in health test participants. Through communication with the FDA, the project did not require a single-dose slope climbing study. At the same time, the FDA also acknowledged the supporting role of China's multi-dose climbing study data in subsequent global research and research on patients with myasthenia gravis.